Death Ligands Designed to Kill: Development and Application of Targeted Cancer Therapeutics Based on Proapoptotic TNF Family Ligands

摘要: The identification of molecular markers associated with cancer development or progression, opened a new era in the therapeutics. successful introduction few low weight chemicals and recombinant protein therapeutics targeted actions into clinical practice have raised great expectations to broadly improve therapy respect both overall responses tolerability. Targeting apoptotic machinery malignant cells is an attractive concept combat cancer, which currently exploited for proapoptotic members TNF ligand family at various stages preclinical development. This review summarizes recent progress this rapidly progressing field “biologic” therapies targeting death receptors TNF, CD95L, TRAIL by means its cognate ligands, receptor specific antibodies, gene therapeutic approaches. Preclinical data on newly derived variants fusion proteins based these designed act tumor restricted manner, thereby preventing systemic, potentially harmful action, will also be discussed.